Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes

Shao, Jie; Xu, Qiuping; Su, Shih Bin; Wei, Jia; Meng, Fanyan; Chen, Fangjun; Zhao, Yang; Du, Juan; Zou, Zhengyun; Qian, Xiaoping; Liu, Baorui

doi:10.1016/j.cellimm.2018.10.002

Cited by 16 publications

(13 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…aAPC are superior to dendritic cells for activating the cytotoxic T-cells against the specific antigen [ 214 ]. This approach is extensively being explored for cancer immunotherapy [ 215 ].…”

Section: Clinical Approachesmentioning

confidence: 99%

Emerging Therapeutic Modalities against COVID-19

et al. 2020

View full text Add to dashboard Cite

The novel SARS-CoV-2 virus has quickly spread worldwide, bringing the whole world as well as the economy to a standstill. As the world is struggling to minimize the transmission of this devastating disease, several strategies are being actively deployed to develop therapeutic interventions. Pharmaceutical companies and academic researchers are relentlessly working to investigate experimental, repurposed or FDA-approved drugs on a compassionate basis and novel biologics for SARS-CoV-2 prophylaxis and treatment. Presently, a tremendous surge of COVID-19 clinical trials are advancing through different stages. Among currently registered clinical efforts, ~86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators. The rest ~14% of clinical efforts are aimed at evaluating vaccines and convalescent plasma-based therapies to mitigate the disease's symptoms. This review provides a comprehensive overview of current therapeutic modalities being evaluated against SARS-CoV-2 virus in clinical trials.

show abstract

Section: Clinical Approachesmentioning

confidence: 99%

Emerging Therapeutic Modalities against COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CTL and NK cells killing activity assays are widely employed to examine cellular immune response levels. NK cells and Cytotoxic lymphocytes (CTLs) are two primary lymphocytes (Schwarz et al., 2013 ; Shao et al., 2018 ). CTLs are part of the CD8 + subset of T cells and demonstrates the presence of T-cell receptors (TCRs).…”

Section: Discussionmentioning

confidence: 99%

DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation

et al. 2020

View full text Add to dashboard Cite

“…have reported genetic engineering of these cells to express HLA, CD80, and 4‐1BBL and incubated them with tumor antigens to generate aAPCs. [ 253 ] The developed aAPC or DC cells treated with the same antigens were cocultured with the cytotoxic TCs in comparable ratios and it was revealed that aAPCs induced more expansion in antigen‐specific TCs than the DCs. The population of TCs being activated via aAPCs contained more effector memory TCs highly expressing CD27 compared to the TC population being activated with DCs.…”

Section: Artificial Immune Cells For Therapeutic Aimsmentioning

confidence: 99%

Chemically Engineered Immune Cell‐Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools

et al. 2021

View full text Add to dashboard Cite

Over the past decades, considerable attention has been dedicated to the exploitation of diverse immune cells as therapeutic and/or diagnostic cell-based microrobots for hard-to-treat disorders. To date, a plethora of therapeutics based on alive immune cells, surface-engineered immune cells, immunocytes' cell membranes, leukocyte-derived extracellular vesicles or exosomes, and artificial immune cells have been investigated and a few have been introduced into the market. These systems take advantage of the unique characteristics and functions of immune cells, including their presence in circulating blood and various tissues, complex crosstalk properties, high affinity to different self and foreign markers, unique potential of their on-demand navigation and activity, production of a variety of chemokines/cytokines, as well as being cytotoxic in particular conditions. Here, the latest progress in the development of engineered therapeutics and diagnostics inspired by immune cells to ameliorate cancer, inflammatory conditions, autoimmune diseases, neurodegenerative disorders, cardiovascular complications, and infectious diseases is reviewed, and finally, the perspective for their clinical application is delineated.

show abstract

Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes

Cited by 16 publications

References 57 publications

Emerging Therapeutic Modalities against COVID-19

Emerging Therapeutic Modalities against COVID-19

DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation

Chemically Engineered Immune Cell‐Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools

Contact Info

Product

Resources

About